These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3184485)

  • 1. [Role of PDGF on myeloproliferative disorders].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
    Yonekura S
    Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
    [No Abstract]   [Full Text] [Related]  

  • 3. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 4. Myelofibrosis in myeloproliferative disorders.
    Srinivasan U; Talvalkar GV; Advani SH
    Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
    Kimura A; Katoh O; Kuramoto A
    Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelofibrosis: a role for platelet derived growth factor (PDGF)?
    Romano M; Poggi A
    Haematologica; 1986; 71(5):359-61. PubMed ID: 3096830
    [No Abstract]   [Full Text] [Related]  

  • 9. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
    Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
    Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
    Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
    J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
    Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
    Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
    Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
    Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet-derived growth factor: mechanism of action and role in the development of diseases].
    Almazov VA; Blagosklonnyĭ MV; Zaritskiĭ AIu
    Ter Arkh; 1984; 56(7):144-7. PubMed ID: 6385321
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of growth factors of platelets (PDGF, TGF-beta, EGF) in the pathogenesis of myelofibrosis].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Byori; 1989 Apr; Spec No 81():1-8. PubMed ID: 2787864
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
    Nagao T; Yonekura S
    Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
    [No Abstract]   [Full Text] [Related]  

  • 19. [Basic and clinical study of platelet-derived growth factor gene expression].
    Takimoto Y; Kimura A
    Rinsho Ketsueki; 1994 Apr; 35(4):364-9. PubMed ID: 8028181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelofibrosis in the myeloproliferative disorders.
    Ellis JT; Peterson P
    Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.